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Abstract: Certain skin pathologies, including psoriasis, are thought to be immune-mediated 
inflammatory diseases. Available literature clearly indicates the involvement of inflammatory 
cells (neutrophils, T cells, and macrophages), their cytokines, and the p38 mitogen-activated pro-
tein kinase (MAPK) signaling pathway in the pathophysiology of psoriasis. Neutrophils play an 
important role in the formation of acute inflammatory changes in psoriasis. Acute inflammation 
or acute flares in psoriasis remain poorly addressed in clinical medicine. In this communication, 
we first establish a simple and reproducible model for studying neutrophil-mediated acute skin 
inflammation. Using the hairless guinea pig, due to the similarity of skin architecture to that of 
human, acute inflammation was induced with an intradermal injection of 50 µg/mL lipopolysac-
charide (LPS) in 50 µL solution. Myeloperoxidase (MPO) activity was measured by MPO-positive 
neutrophils and shown to increase for 24-hours post-injection. Simultaneously, the level of phos-
phorylated p38 MAPK was documented for 48-hours post-LPS injection in the skin. Next, we used 
this model to examine the therapeutic potential of an α-selective p38 MAPK inhibitor, SCIO-469. 
A comparison of topical application of SCIO-469 at 5 mg/mL or 15 mg/mL to vehicle revealed 
that SCIO-469 dose-dependently reduces acute skin inflammation and that this effect is statistically 
significant at the higher dose. Further examination of tissues that received this dose also revealed 
statistically significant reduction of MPO activity, phosphorylated p38 MAPK, interleukin-6, and 
cyclooxygenase-2. These data suggest that the α-selective p38 MAPK inhibitor, SCIO-469, acts as 
a topical anti-inflammatory agent via the p38 MAPK pathway to reduce neutrophil induced acute 
inflammation in the skin. These observations suggest that α-selective p38 MAPK inhibition may 
be an effective therapeutic strategy to manage acute skin inflammation
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Introduction
Immune-mediated inflammation is thought to underlie certain skin diseases, including 
psoriasis.1,2 Psoriatic patients have increased numbers of circulating neutrophils, 
which also appear early in the formation of new lesions Historical data clearly 
suggests involvement of inflammatory cells (neutrophils, T cells, and macrophages) 
and their cytokines tumor necrosis factor-alpha (TNFα), interleukin (IL)-1β, IL-6, 
IL-8 and cycloxygenase-2 (COX-2) in the initiation, development and maintenance 
of the psoriatic lesions as well as in induction of acute flares.3–5 Neutrophils play 
an important role in the formation of the acute inflammatory changes in psoriasis, 
while chronic inflammation is well explained by a T cell-associated inflammation-
sustaining loop.6 Treatment of acute inflammation or acute flares in psoriasis is an 
unmet medical need.4,5,7,8 The p38 mitogen-activated protein kinase (MAPK) signaling Journal of Inflammation Research 2010:3 10
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pathway is active in inflammatory skin diseases9–11 and 
inhibitors of this pathway reduce skin inflammation in vari-
ous rodent models of human skin diseases.12,13 SCIO-469 is 
a p38 MAPK inhibitor which has been tested clinically as an 
oral agent in several patient populations, but has not yet been 
tested in humans using topical application. A major roadblock 
in the identification and development of topical treatments 
for psoriasis is the structural dissimilarity of rodent and 
human skin. In guinea pigs and humans, the thickness of 
stratum corneum and epidermis is similar and there is a 
very good correlation of in vivo transdermal drug delivery 
between these two species.14 Further, erythema and edema 
during skin inflammation are highly similar for these two 
species. An intermittent exudate of fluid and of leukocytes, 
both neutrophils and lymphocytes, are seen in the epidermis 
in early psoriasis. This early histology has been reconfirmed 
several times with neutrophil presence and basal keratinocyte 
changes in psoriatic patients.15 Hence, neutrophils infiltration 
as measured by myeloperoxidase (MPO) activity was used 
to assess the effect of p38 MPAK inhibition on acute skin 
inflammation in guinea pigs.
In the first part of the present communication, we describe 
a guinea pig model of acute skin inflammation that is driven 
by the activation of the p38 MAPK signaling pathway. 
Lipopolysaccharide (LPS) was used as an inducer of acute 
skin inflammation. LPS is known to activate p38 MAPK 
signaling14,16,17 and initiates infiltration by inflammatory cells, 
especially neutrophils,18 into the skin and promotes a cascade 
of events that includes the release of cytokines,19 protease 
activation,20 free radical generation,20 and skin apoptosis.21 
After pilot studies examining the dose-response effects of 
intradermal LPS (derived from Salmonella typhimurium) at 
doses of 0, 25, 50 and 100 µg in a volume of 50 µL vehicle for 
a period of 48-hours, we chose the 50 µg/mL dose of LPS for 
subsequent testing, as this dose caused a significant amount 
of phosphorylation of p38 and infiltration of neutrophils into 
the skin by 24-hours.
In the second part of the present communication, this 
model was used to examine the therapeutic potential of 
SCIO-469 in topical application in its base form. SCIO-469 
is a small molecule α-selective p38 MAPK inhibitor that 
is structurally similar to SD-282 or/and SD-169, and has 
been tested in oral formulations in clinical studies for other 
inflammatory conditions.22 No toxicities have been reported 
with SCIO-469 in animal models.23–25 Both SD-282 and 
SD-169 have been previously shown to inhibit inflammatory 
infiltration and cytokine release in various animal models of 
inflammatory diseases.24,25
Materials and methods
scIo-469 chemical structure, 
potency, and specificity
SCIO-469 is an orally active indole-5-carboxamide, ATP-
competitive inhibitor of p38 kinase. The half maximum 
inhibitory concentration (IC50) of SCIO-469 for human p38 
MAPKs α, β, γ, and δ isoforms were determined in dupli-
cate using ELISA assays adapted from published methods.26 
Purified human recombinant (Escherichia coli) p38 MAPK 
isoforms were incubated with substrate (Myelin Basic Protein 
[MBP], 10.75 µg/mL) in the presence of inhibitor or control 
in a buffer comprised of 50 mM Hepes, 20 mM MgCl2, 
0.2 mM Na3VO4, 1 mM DTT, pH 7.4 for 60 minutes at 25 °C. 
The readout was ELISA quantitation of incorporation of ATP 
into MBP (MDS Pharma, Tampa, FL USA). Enzyme con-
centrations were as follows: 75 ng/mL for p38α; 250 ng/mL 
for p38β, p38γ, and p38δ. The adenosine triphosphate (ATP) 
concentration was previously optimized for each assay and 
was 100 µM in the p38α assay, 10 µM in the p38β assay, 
1 µM in the p38γ assay, and 3 µM in the p38δ assay. The 
control for the α and β isoforms was SB 202190 and for the 
γ and δ isoforms the control was staurosporine. The IC50 
values of SCIO-469 revealed a 10-fold selectivity for p38α 
MAPK (IC50 value of 0.01 µM) compared to p38β MAPK 
(IC50 value of 0.1 µM), whereas inhibition of p38γ MAPK 
and p38δ MAPK was less than 50%, even at concentrations 
of 10 µM. When tested in vitro at a concentration of 10 µM, 
SCIO-469 demonstrated no inhibitory activity against a panel 
of other kinases including ERK2, JNK-1, and MAPKAPK-2. 
In addition, SCIO-469 demonstrates no effect on the activity 
of purified COX-1 or COX-2 enzymes.
Animals
All experiments were carried out according to protocols 
approved by the Institutional Animal Care Committee of 
SCIOS, Inc. (Fremont, CA USA). Thirty guinea pigs were 
housed in accordance with the National Institute of Health 
guidelines in micro-isolator filter cages and maintained on a 
12-hour light/dark cycle with free access to food and water. 
Upon study initiation, guinea pigs were individually housed 
in solid bottomed cages with Alpha Dry bedding.
guinea pig model of lPs-induced, 
neutrophil-, and p38 MaPK-driven 
skin inflammation
The entire back of the thirty guinea pigs was washed gently 
from the dorsal scapular area to the dorsal lumbo-sacral area Journal of Inflammation Research 2010:3 11
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with alcohol wipes, rinsed with 0.9% saline and allowed to dry. 
Each guinea pig was injected (26 gauge needle/1.0 mL glasses 
Hamilton micro syringe) with LPS at a dose of 50 µg/mL in 
a 50-µL volume of saline into the skin. The injection site 
was marked with a Shur/Mark marker (Triangle Biomedical 
Sciences, Durham, NC). The marker was used to place a line 
from the injection site across the bleb to show the histologist 
the direction of injection. Thirty guinea pigs were divided into 
six groups each consisting of five guinea pigs and they were 
sacrificed at 2-, 4-, 6-, 8-, 24-, and 48-hour time points, respec-
tively. Skin was bisected from the LPS injected dot, which 
was marked by black dye. Skin punch biopsies were saved for 
immunohistochemical (IHC) analysis of MPO, a marker for 
neutrophil infiltration into the skin, and for phosphorylated 
p38 MAPK (pp38). The tissue was fixed with 10% formalin, 
processed and paraffin embedded on edge. Total neutrophils 
(labelled with MPO) infiltrated in derma were automatically 
counted throughout the inflammatory area (six fields) under 
20× magnification with the aid of Image Pro Plus (Media 
Cybernetics, Silver Spring, MD USA).
Ihc staining protocol for myeloperoxidase 
(MPO) activity
The primary antibody (Rabbit MPO Ab-1) was obtained from 
Lab Vision Corp (formerly Neo Markers; Fremont, CA USA), 
and secondary antibody (Goat Anti-Rabbit Biotinlated IgG) 
from Chemicon International, Inc. (Temecula, CA USA). Nega-
tive control antibody (Normal Rabbit IgG) was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA USA). Based on 
the intensity, distribution and number of the positively stained 
neutrophils, a score was assigned as 0 for none, 1 for mild, 2 for 
moderate, 3 for strong, 4 for severe, and 5 for robust.
Ihc staining protocol for phosphorylated p38 MaPK
Rabbit anti-phospho-p38, which is a polyclonal IgG antibody, 
was purchased from Cell Signalling Technologies (Danvers, 
MA USA). Secondary antibody, goat anti-rabbit biotinlated 
IgG, was obtained from Chemicon International, Inc. Normal 
rabbit IgG from Santa Cruz Biotechnology was used in the 
negative control. Based on the intensity, distribution and number 
of the positively stained cells, a score was assigned with 0 for 
none, 1 for mild, 2 for moderate, and 3 for severe.
Test of the effect of topical scIo-469 
on skin inflammation
We first conducted a dose-response study with SCIO-469. 
SCIO-469 free base in 20% isopropanol and 80% propylene. 
The ethyl glycol-400 (IPA-PEG-400) was prepared in two 
concentrations, 5 mg/mL and 15 mg/mL. The entire backs of 
thirty guinea pigs were washed gently from the dorsal scapular 
area to the dorsal lumbo-sacral areas with alcohol wipes, 
rinsed with 0.9% saline and dried. Each guinea pig received a 
single intraderma injection of 50 µg LPS in 50 µL vehicle at 
the dorsal midline close to the scapular region. Soon after the 
injection, animals were randomized into three treatment groups 
each consisting of 10 guinea pigs. With an aid of a Hill Top 
Chamber (Hill Top Research, Miamiville, OH USA), Groups 
1, 2, and 3 received topical IPA-PEG-400 (vehicle), SCIO-469 
at 5 mg/mL and SCIO-469 at 15 mg/mL, respectively. Briefly, 
a Hilltop chamber was filled with the respective solutions and 
placed on the injection site of the skin for continuous topical 
administration. The chamber was affixed with a piece of 1-inch 
waterproof veterinary surgical tape. The animals were moni-
tored periodically throughout the day by an associate scientist 
to prevent the removal of the surgical tape and the Hilltop 
chamber. The wrap was removed 8-hours after its placement 
and the Hilltop chamber was refilled and reapplied with the 
respective solutions. In addition, to prevent removal overnight, 
the chambers were secured by wrapping a piece of 3-inch 
Coban Self-Adherent Wrap around the guinea pig's torso and 
back. The animals were returned to their cages and observed 
for behavioral signs of discomfort or pain. Care was taken to 
wrap securely but still loosely enough to avoid irritation. Ani-
mals were closely observed during the 24-hour study period 
except between the hours of 7 PM to 7 AM. All observations 
and adjustments with respect to the secured state of the Hilltop 
chambers and pain/distress were recorded. Guinea pigs were 
euthanized 24-hours after the initiation of the study and skin 
punch biopsies were saved for hematoxylin and eosin (H&E) 
analysis, for skin inflammation at a gross level and microscopic 
level (IHC for MPO). The IHC analysis for MPO was conduced 
as described above.
analysis of phosphorylated p38 MaPK, 
Il-6, and coX-2
Using skin punch biopsies, IHC analysis of pp38 was con-
ducted as described above. Goat anti-mouse IL-6 from R&D 
System (Minneapolis, MN USA) was used as a primary 
antibody. Donkey anti-Goat biotinlated IgG was used as 
a secondary antibody (Chemicon International, Inc). For 
a negative control, normal goat IgG was purchased from 
Santa Cruz Biotechnology. COX-2 primary antibody was 
purchased from Alexis Biochemicals (San Diego, CA). The 
secondary antibody, goat anti-rabbit biotinylated IgG, was 
purchased from Chemicon International, Inc. The negative 
antibody was rabbit IgG which was purchased from Santa 
Cruz Biotechnology. Based on the intensity, distribution and Journal of Inflammation Research 2010:3 12
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number of the positively stained neutrophils, endothelial cells 
and macrophages a score was assigned as
None = 0
100 to 299 MPO positive cells/field = 1
300 to 399 MPO positive cells/field = 2
400 to 499 MPO positive cells/field = 3
500 to 599 MPO positive cells/field = 4
600 MPO positive cells/field = 5.
statistical analysis
Analyses were carried out using Graph Pad statistical analysis 
software (San Diego, CA USA). Comparative data sets whose 
differences reached a level of significance of P  0.05 were 
defined as statistically significant.
Results
lPs induces a neutrophil- and p38 MaPK-
driven skin inflammation in guinea pigs
Administration of LPS induced dose- and time-dependent 
increases in phosphorylation of p38 MAPK and infiltration 
of neutrophils was measured by MPO activity (data not 
shown). The maximum effect on neutrophils was observed 
at a dose of 50 µg/mL at 24-hours time point. There was no 
observable phosphorylation or infiltration of neutrophils in 
the vehicle control at 8-, 24-, and 48-hour time points which 
suggests that there is no needle effect.
LPS intradermal injection at a dose of 50 µg in a 50 µL 
volume induced a neutrophil-mediated skin inflammation 
that increased monotonically over time, beginning at 6-hours 
post-injection and reaching a maximum level by 24-hours. 
LPS induced elevation of neutrophil infiltration was statisti-
cally significant by 6-hours (P  0.005) when compared 
to the 2-hour time point. The increase remains statistically 
significant at 8-, 24-, and 48-hours (P  0.01, P  0.001 
and P  0.001, respectively) (Figure 1A). Phosphorylated 
p38 MAPK was observable in neutrophils and endothelial 
cells beginning at 8-hours post-injection and continued for 
48-hours (Figure 1B). The increases in pp38 are statistically 
significant at 8-, 24-, and 48-hour time points where P values 
were  0.05,  0.01, and  0.001, respectively, when com-
pared to the two-hour time point. Neutrophils infiltration 
increased for 24-hours post-injection, with phosphorylated 
p38 MAPK levels continuing to rise for at least another 
24-hours thereafter. A maximal response was obtained 
24-hours after dosing with 50 µg/mL LPS/site.
We chose the 50 µg/mL dose for subsequent studies. 
This dose caused significant increase in phosphorylated 
p38 MAPK and infiltration of neutrophils into the skin by 
24-hours when compared to the vehicle control, allowing 
study of the acute therapeutic effect of SCIO-469. For practi-
cal purposes, the short duration of the study minimizes the 
time required for securing the Hilltop chambers.
Topical scIo-469 reduces skin 
inflammation in guinea pig
Topical administration of SCIO-469 dose-dependently 
reduced skin inflammation as observed grossly (Figure 2A), 
and at a cellular level, where neutrophil infiltration as mea-
sured by MPO activity was reduced (Figure 2B). The effects 
are statistically significant at the higher dose SCIO-469 
(15 mg/mL; P  0.001) when compared to the vehicle 
group. Immunohistochemical studies reveal that SCIO-469 
at the higher dose significantly reduced IL-6 expression in 
neutrophils and endothelial cells (Figure 3, upper panel; 
P  0.001) and reduced COX-2 expression in neutrophils, 
endothelial cells, macrophages and fibroblasts (Figure 3, 
middle panel; P  0.001). Further, SCIO-469 at the higher 
dose significantly reduced pp38 MAPK in neutrophils and 
endothelial cells (Figure 3, lower panel; P  0.01).
Discussion
In the present study, we established a model system for 
studying neutrophil-mediated acute skin inflammation and its 
sequelae, for testing potential topical therapies. The model is 
simple and reproducible (Medicherla unpublished observa-
tions, 2005), involving induction with LPS. 50 µg/mL LPS 
were gauged to maximally induce neutrophils at 24-hours 
post-injection, with phosphorylated p38 MAPK levels con-
tinuing to rise for at least another 24-hours thereafter. This 
dose and time was used in designing the current studies of the 
therapeutic potential of topical administration of α-selective 
p38 inhibitor, SCIO-469.
We undertook to examine the therapeutic potential of 
SCIO-469 in topical application in its base form in 20% 
isopropanol alcohol and 80% propylene ethyl glycol-400 
(IPA-PEG-400). A comparison of SCIO-469 at 5 mg/mL or 
15 mg/mL versus vehicle revealed that only the higher dose 
gave a statistically significant improvement of inflammation 
over vehicle treatment. Further examination of tissues that 
had received this dose revealed statistically significant reduc-
tion of neutrophils (P  0.001), pp38 MAPK (P  0.0001), 
IL-6 (P  0.05), and COX-2 (P  0.001) whereas the lower 
did not.
Neutrophils play an important role in the forma-
tion of acute inflammatory changes in psoriasis, while Journal of Inflammation Research 2010:3 13
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chronic inflammation in psoriasis is well explained by a 
T cell-associated inflammation-sustaining loop.6 Patients 
with moderate to severe psoriasis experience significant 
deterioration in quality of life.27 Acute flares can evolve into a 
more severe disease due to enhanced neutrophil cytotoxicity.28 
Currently, management of acute flares in psoriasis are a clini-
cal challenge. It is evident from the present study that SCIO-
469 significantly reduces acute neutrophil infiltration into the 
skin, which suggests it is capable of effecting at least one key 
element in formation of acute inflammatory changes in psori-
atic flares. Further, in psoriatic patients with acute flares, there 
is a diminished axon-reflex function due to a down regulation 
of C-fiber neuronal firing.29 SD-282, which is a structural and 
functional analogue of SCIO-469, and which has recently 
been shown to reduce the firing or release of calcitonin gene-
related peptide from these nerve endings.30 Intriguingly, no 
side effect was seen at topical dose (50 µg/mL) used in this 
study or when given at a dose of 15 mg/kg/oral in guinea 
pigs (unpublished) or 30 mg/kg/oral in rats.22 Together, these 
observations suggest that an α-selective p38 inhibitor may 
be a promising therapeutic approach to reduce neutrophil 
mediated acute flares in psoriasis.
Available literature also indicates a pattern in formation 
of acute flares in psoriatic patients in which stress and other 
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Figure 1 Time-dependent infiltration of neutrophils and phosphorylation of p38 in the skin.   a dose of 50 µg/ml lPs in a 50 µL injection volume induced neutrophil-mediated 
skin inflammation as measured by MPo activity increased monotonically over time, beginning at 6-hours post-injection and reaching a maximum level by 24-hours when com-
pared to the two-hour time point (A; *P  0.05; *P  0.005; ***P  0.001). Phosphorylated p38 MaPK was observable in neutrophils and endothelial cells beginning at 8-hours 
post-injection and continued for 48-hours (B; *P  0.05; **P  0.01; ***P  0.001 compared to two-hour time point).   Values are reported as the mean ± sD; n = 10.
Abbreviations: lPs, lipopolysaccharide; MaPK, mitogen-activated protein kinase; MPo, myeloperoxidase; pp38, phosphorylated p38; sD, standard deviation.Journal of Inflammation Research 2010:3 14
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conditions play a major role,4,5,7,8 and p38 MAPK signaling 
is upregulated in stressful states.31 This opens a modality to 
manage these acute flares in a prophylactic manner based 
on psoriatic patients’ episodic clinical history.7 Similar to 
its therapeutic application, a prophylactic application of 
an α-selective p38 MAPK inhibitor may be of value in the 
prevention of acute flares for psoriasis patients.
We conclude that topical administration of α-selective 
p38 MAPK inhibitor SCIO-469 acts as an anti-inflammatory 
agent via inhibition of the p38 MAPK signalling pathway to 
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Figure 2 scIo-469 dose-dependently reduces neutrophil-derived skin inflammation. scIo-469 dose-dependently reduced skin inflammation in gross observation. left panel 
from vehicle group and right panel from topical scIo-469 at 15 mg/ml;  A) and neutrophil driven inflammation as measured by MPo activity B). Data are statistically significant 
at high dose (15 mg/ml; *P  0.001). Values are reported as the mean ± sD; n = 10, 40/200× (upper/lower). Figure 2a is at 40/200× magnification.
Abbreviations: MPo, myeloperoxidase; sD, standard deviation.Journal of Inflammation Research 2010:3 15
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reduce neutrophil driven acute skin inflammation. These results 
suggests that α-selective p38 MAPK inhibition may be an effec-
tive therapeutic strategy to manage acute skin inflammation.
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